BIO Submits Comments Re: Nondiscrimination in Health Programs and Activities
<div>
The Biotechnology Industry Organization (BIO) is pleased to submit the following comments in response to the Department of Health and Human Services’ (HHS’s) Proposed Rule entitled “Nondiscrimination in Health Programs and Activities” published on September 8, 2015 (the “Proposed Rule”).1 BIO represents biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO’s members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place. In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, but also have reduced healthcare expenditures due to fewer physician office visits, hospitalizations, and surgical interventions.</div>
